The role of IVIg treatment in severe pemphigus vulgaris
Authors:
- 21 April 2006
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (5) , 548-552
Abstract
Background High‐dose intravenous immunoglobulin (IVIg) has become a part of the treatment armentarium in pemphigus vulgaris (PV). Some consider IVIg as an adjuvant steroid sparing agent in PV, while others as disease modifying that can be used as monotherapy.Methods We report our experience with a series of 12 PV patients with severe disease treated with IVIg as an adjuvant therapy.Results Ten of 12 patients (83%) showed response to six cycles of IVIg, six (50%) having complete remission and four (33%) having a partial response. This response rate is concordant with previous reports. The therapy was well tolerated. In all 12 patients, treatment with IVIg allowed a gradual reduction of prednisone dose compared with baseline levels.Conclusion IVIg treatment was beneficial as a steroid sparing agent in our series of patients with severe PV.Keywords
This publication has 14 references indexed in Scilit:
- Efficacy and Safety of Intravenous Immunoglobulin for Immune-Mediated Skin DiseaseAmerican Journal of Clinical Dermatology, 2004
- Treatment of pemphigus with intravenous immunoglobulinJournal of the American Academy of Dermatology, 2002
- Corticosteroid-Sparing Effect of Intravenous Immunoglobulin Therapy in Patients With Pemphigus VulgarisArchives of Dermatology, 2002
- High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disordersClinical and Experimental Immunology, 2002
- Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapyJournal of the American Academy of Dermatology, 2002
- Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatmentJournal of the American Academy of Dermatology, 2001
- A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disordersClinical and Experimental Dermatology, 2001
- Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgarisJournal of the American Academy of Dermatology, 2000
- Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy?British Journal of Dermatology, 1998
- Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patientsBritish Journal of Dermatology, 1995